Persistence, adherence, and all-cause healthcare costs in atazanavir- and darunavir-treated patients with human immunodeficiency virus in a real-world setting

References

• Monitoring selected national HIV prevention and care objectives by using HIV surveillance data–United States and 6 U.S. dependent areas–2011. Atlanta, GA: Centers for Disease Control and Prevention, 2013. http://www.cdc.gov/hiv/pdf/2011_Monitoring_HIV_Indicators_HSSR_FINAL.pdf. Accessed September 30, 2014
   Google Scholar
• Bhaskaran K, Hamouda O, Sannes M, et al. Changes in the risk of death after HIV seroconversion compared with mortality in the general population. JAMA 2008;300:51-9
   PubMed Web of Science ®Google Scholar
• Lima VD, Harrigan R, Bangsberg DR, et al. The combined effect of modern highly active antiretroviral therapy regimens and adherence on mortality over time. J Acquir Immune Defic Syndr 2009;50:529-36
   PubMed Web of Science ®Google Scholar
• Maggiolo F, Ravasio L, Ripamonti D, et al. Similar adherence rates favor different virologic outcomes for patients treated with nonnucleoside analogues or protease inhibitors. Clin Infect Dis 2005;40:158-63
   PubMed Web of Science ®Google Scholar
• Nachega JB, Hislop M, Dowdy DW, et al. Adherence to nonnucleoside reverse transcriptase inhibitor-based HIV therapy and virologic outcomes. Ann Intern Med 2007;146:564-73
   PubMed Web of Science ®Google Scholar
• Sethi AK, Celentano DD, Gange SJ, et al. Association between adherence to antiretroviral therapy and human immunodeficiency virus drug resistance. Clin Infect Dis 2003;37:1112-18
   PubMed Web of Science ®Google Scholar
• Bae JW, Guyer W, Grimm K, et al. Medication persistence in the treatment of HIV infection: a review of the literature and implications for future clinical care and research. AIDS 2011;25:279-90
   PubMed Web of Science ®Google Scholar
• O'Connor JL, Gardner EM, Mannheimer SB, et al. Factors associated with adherence amongst 5295 people receiving antiretroviral therapy as part of an international trial. J Infect Dis 2013;208:40-9
   PubMed Web of Science ®Google Scholar
• Sax PE, Meyers JL, Mugavero M, et al. Adherence to antiretroviral treatment and correlation with risk of hospitalization among commercially insured HIV patients in the United States. PLoS One 2012;7:e31591
   PubMed Web of Science ®Google Scholar
• Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Washington, DC: Department of Health and Human Services Panel on Antiretroviral Guidelines for Adults and Adolescents, http://aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf. Accessed May 6, 2015
   Google Scholar
• Reyataz Prescribing Information. Princeton, NJ: Bristol-Myers Squibb, 2015. http://packageinserts.bms.com/pi/pi_reyataz.pdf. Accessed May 6, 2015
   Google Scholar
• Prezista Prescribing Information. Titusville, NJ: Janssen Pharmaceuticals, 2013. https://www.prezista.com/sites/default/files/pdf/us_package_insert.pdf. Accessed May 6, 2015
   Google Scholar
• Cahn P, Pozniak AL, Mingrone H, et al. Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naïve adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study. Lancet 2013;382:700-8
   PubMed Web of Science ®Google Scholar
• Molina JM, Lamarca A, Andrade-Villanueva J, et al. Efficacy and safety of once daily elvitegravir versus twice daily raltegravir in treatment-experienced patients with HIV-1 receiving a ritonavir-boosted protease inhibitor: randomised, double-blind, phase 3, non-inferiority study. Lancet Infect Dis 2012;12:27-35
   PubMed Web of Science ®Google Scholar
• Consumer Price Index Detailed Report January 2014. Washington, DC: US Bureau of Labor Statistics, http://www.bls.gov/cpi/cpid1401.pdf. Accessed September 30, 2015
   Google Scholar
• AIDS-defining conditions, ICD-9-CM codes for AIDS indicator diseases. Harrisburg, PA: Pennsylvania Department of Health. http://www.portal.state.pa.us/portal/server.pt/community/hiv___aids/14241/attachment_archive/557348. Accessed February 6, 2015
   Google Scholar
• D'Agostino RB Jr. Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med 1998;17:2265-81
   PubMed Web of Science ®Google Scholar
• Johnston SS, Juday T, Farr AM, et al. Comparison between guideline-preferred and non-preferred first-line HIV antiretroviral therapy. Am J Manag Care 2014;20:448-55
   PubMed Web of Science ®Google Scholar
• Juday T, Farr AM, Johnston SS, et al. Antiretroviral adherence among Medicaid-insured HIV patients initiating current guideline-preferred antiretroviral therapy regimens. Poster presented at: International Society of Pharmacoeconomics and Outcomes Research 18th Annual International Meeting; May 2013; New Orleans, LA
   Google Scholar
• Juday T, Johnston SS, Farr AM, et al. Healthcare expenditures among Medicaid-insured HIV patients initiating antiretroviral therapy regimens “preferred” under current treatment guidelines in the United States. Poster presented at: International Society of Pharmacoeconomics and Outcomes Research 18th Annual International Meeting; May 2013; New Orleans, LA
   Google Scholar
• Johnston SS, Juday T, Esker S, et al. Comparative incidence and health care costs of medically attended adverse effects among U.S. Medicaid HIV patients on atazanavir- or darunavir-based antiretroviral therapy. Value Health 2013;16:418-25
   PubMed Web of Science ®Google Scholar
• Brown TT, Moser C, Currier J, et al. Changes in bone mineral density after initiation of antiretroviral treatment with tenofovir disoproxil fumaratre/emtricitabine plus atazanavir/ritonavir, darunavir/ritonavir, or raltegravir. J Infect Dis 2015;212:1241-9
   PubMed Web of Science ®Google Scholar
• Ofotokun I, Na LH, Landovitz RJ, et al. Comparison of the metabolic effect of ritonavir-boosted darunavir or atazanavir versus raltegravir, and the impact of ritonavir plasma exposure: ACTG 5257. Clin Infect Dis 2015;60:1842-51
   PubMed Web of Science ®Google Scholar
• Lapadula G, Costarelli S, Chatenoud L, et al. Risk of liver enzyme elevation during treatment with ritonavir-boostesd protease inhibitors among HIV mono-infected and HIV/HCV-coinfected patients. J Acquir Immune Defic Syndr 2015;69:312-18
   PubMed Web of Science ®Google Scholar
• Aberg JA, Tebas P, Overton ET, et al. Metabolic effects of darunavir/ritonavir versus atazanavir/ritonavir in treatment-naïve, HIV type 1-infected subjects over 48 weeks. AIDS Res Hum Retroviruses 2012;28:1184-95
   PubMed Web of Science ®Google Scholar
• Stein JH, Ribaudo HJ, Hodis HN, et al. A prospecitve randomized clinical trial of antiretroviral therapies on carotid wall thickness. AIDS 2015;29:1775-83
   PubMed Web of Science ®Google Scholar
• Saumoy M, Ordonez-Llanos J, Martinez E, et al. Atherogenic properties of lipoproteins in HIV patients starting atazanavir/ritonavir or darunavir/ritonavir: a substudy of the ATADAR randomized study. J Antimicrob Chemother 2015;70:1130-8
   PubMed Web of Science ®Google Scholar
• Martinez E, Gonzalez-Cordon A, Ferrer E, et al. Differential body composition effects of protease inhibitors recommended for initial treatment of HIV infection: a randomized clinical trial. Clin Infect Dis 2015;60:811-20
   PubMed Web of Science ®Google Scholar
• Martinez E, Gonzalez-Cordon A, Ferrer E, et al. Early lipid changed with atazanavir/ritonavir or darunavir/ritonavir. HIV Med 2014;15:330-8
   PubMed Web of Science ®Google Scholar
• Lennox JL, Landovitz RJ, Ribaudo HJ, et al. Efficacy and tolerability of 3 nonnucleoside reverse transcriptase inhibitor-sparing antiretroviral regimens for treatment-naïve volunteers infected with HIV-1: a randomized, controlled equivalence trial. Ann Intern Med 2014;161:461-71
   PubMed Web of Science ®Google Scholar
• Cozzi-Lepri A, Antinori A, Bonora S, et al. An observational comparison of first-line combination antiretroviral treatment (cART) with 2 NRTI and ATV/r or DRV/r in HIV-infected patients in Italy. J Int AIDS Soc 2014;17(4 Suppl 3):19771
   PubMedGoogle Scholar
• Jarrin I, Hernandez-Novoa B, Alejos B, et al. Persistence of novel first-line antiretroviral regimes in a cohort of HIV-positive subjects, CoRIS 2008-2010. Antivir Ther 2013;18:161-70
   PubMed Web of Science ®Google Scholar
• Lillie-Blanton M, Stone VE, Jones AS, et al. Association of race, substance abuse, and health insurance coverage with use of highly active antiretroviral therapy. Am J Public Health 2010;100:1493-9
   PubMed Web of Science ®Google Scholar
• Schneider G, Juday T, Wentworth C 3rd, et al. Impact of health care payer type on HIV stage of illness at time of initiation of antiretroviral therapy in the USA. AIDS Care 2013;25:1470-6
   PubMed Web of Science ®Google Scholar